Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9457374 | 1.00 | CXCR4 (0.40) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL15523093 | 0.97 | — | — | |
| SCHEMBL15523094 | 0.97 | — | — | |
| SCHEMBL21880823 | 0.87 | ALDH1A1 (0.45) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL16583982 | 0.87 | ALDH1A1 (0.45) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL5771150 | 0.86 | — | — | |
| SCHEMBL1779852 | 0.86 | CXCR4 (0.33) | CXCR4SMN1; SMN2 | |
| SCHEMBL10331894 | 0.83 | CXCR4 (0.30) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL6030865 | 0.83 | — | — | |
| SCHEMBL17476601 | 0.82 | ALDH1A1 (0.45) | CXCR4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419619-A1 | SELECTIVE WET ETCH COMPOSITION AND METHOD | Entegris, Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| CN-118234830-A | Selective wet etching composition and method | 恩特格里斯公司 | 2024-06-21 | — | — | CN | claimed |
| EP-4225881-A1 | MICROELECTRONIC DEVICE CLEANING COMPOSITION | Entegris, Inc. (US) | 2023-08-16 | — | — | EP | claimed |
| CN-116438284-A | Microelectronic device cleaning compositions | 恩特格里斯公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023069409-A1 | SELECTIVE WET ETCH COMPOSITION AND METHOD | ENTEGRIS, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2022076252-A1 | MICROELECTRONIC DEVICE CLEANING COMPOSITION | ENTEGRIS, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| CN-113195698-A | Compositions and methods for cleaning POST chemical mechanical polishing (POST-CMP) cobalt substrates | 恩特格里斯公司 | 2021-07-30 | — | — | CN | claimed |
| CN-112996893-A | POST chemical mechanical polishing (POST CMP) cleaning composition | 恩特格里斯公司 | 2021-06-18 | — | — | CN | claimed |
| CN-112771144-A | POST chemical mechanical polishing (POST CMP) cleaning composition for cerium particles | 恩特格里斯公司 | 2021-05-07 | — | — | CN | claimed |
| EP-4735391-A2 | ALKYL SULFONIC ACID COMPOSITIONS USEFUL IN DESCALING APPLICATIONS | Jelmar LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735569-A1 | ALKYL SULFONIC ACID COMPOSITIONS COMPRISING SOLVENT USEFUL IN DESCALING APPLICATIONS | Jelmar LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250302954-A1 | METHODS TO OVERCOME DRUG RESISTANCE BY RE-SENSITIZING CANCER CELLS TO TREATMENT WITH A PRIOR THERAPY VIA TREATMENT WITH A T CELL THERAPY | CELGENE CORPORATION (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3824059-B1 | CLEANING COMPOSITION WITH CORROSION INHIBITOR | ENTEGRIS INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20040162240-A1 | Cobalamin conjugates useful as antitumor agents | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2004-08-19 | — | — | US | disclosed |
| US-4983376-A | Metal complexes | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0198051-A1 | GADOLINIUM CHELATES AS NMR CONTRAST AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-10-22 | — | — | EP | disclosed |
| EP-0198051-A1 | GADOLINIUM CHELATES AS NMR CONTRAST AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-10-22 | — | — | EP | disclosed |
| WO-1986002352-A1 | GADOLINIUM CHELATES AS NMR CONTRAST AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-04-24 | — | — | WO | disclosed |
| WO-1986002352-A1 | GADOLINIUM CHELATES AS NMR CONTRAST AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162240-A1 | Cobalamin conjugates useful as antitumor agents | MMAB, SLC19A2, SLC19A1 | CXCR4 3826/4885SMN1; SMN2 993/4885ALDH1A1 3283/4885 |
| US-20250302954-A1 | METHODS TO OVERCOME DRUG RESISTANCE BY RE-SENSITIZING CANCER CELLS TO TREATMENT WITH A PRIOR THERAPY VIA TREATMENT WITH A T CELL THERAPY | MCL1, CD4, NFATC1 | CXCR4 158/4885SMN1; SMN2 3558/4885ALDH1A1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.